Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Zhang, Guan Zhong ^a   Jiao, Shun Chang ^a   Meng, Zhao Ting ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CISPLATIN; CREATININE; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER STAGING; CREATININE BLOOD LEVEL; DIARRHEA; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; AREA UNDER THE CURVE; CLINICAL TRIAL; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 77951230703     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-38     Document Type: Article

References (32)

1. Ho C, Davies AM, Lara PN Jr, Gandara DR: Second-line treatment for advanced-stage non-small celllung cancer: current and future options. clin lung cancer 2006, 7(Supple 4):118-125.
2. Felip E, Rosell R, Pampaloni G: Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). Ther Clinl Risk Manag 2008, 4(3):579-585.
3. Russo FBA, Pampaloni G: Pemetrexeed single agent chemotherapy in previously treated patients with local advanced or metastatic nonsmall cell lung cancer. BMC Cancer 2008, 8:216-223.
4. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR: American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004, 22:330-353.
5. Marinis F, Grossib F: Clinical evidence for second- And third-line treatment options in advanced non-small cell lung cancer. Oncologist 2008, 13(suppl 1):14-20.
6. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncologist 2004, 22(9):1589-1597.
7. Rollins KD, Lindley C: Pemetrexed: A multitargeted antifolate. Clin Ther 2005, 27(9):1343-1382.
8. Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R: FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005, 10:363-368.
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L: Erlotinib in previously reated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
10. Hanauske AR, Eismann U, Oberschmidt O, Pospisil H, Hoffmann S, Hanauske-Abel H, Ma D, Chen V, Paoletti P, Niyikiza C: In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest new drug 2007, 25(5):417-423.
11. Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, O'Brien M, Peterson PM, Castellano D, Selvaggi G, Novello S, Blatter J, Kayitalire L, Crino L, Paz-Ares L: Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial. Clin Cancer Res 2005, 11:690-696.
12. Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE: A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 2007, 3:515-522.
13. Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H, De Leyn P, Thomas M: Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol. BMC Cancer 2007, 7:77.
14. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. J Clin Oncol 2008, 26:3543-3551.
15. Ricciardi S, Tomao S, de Marinis F: Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. Ther Clin Risk Manag 2009, 5:781-787.
16. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA: The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. Oncologist 2009, 14:253-263.
17. Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C: Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer 2009, 66(2):141-149.
18. Stinchcombe TE, Socinski MA: Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 2009, 6(2):233-241.
19. Stinchcombe TE, Socinski MA: Considerations for second-line therapy of non-small cell lung cancer. Oncologist 2008, 13(Suppl 1):28-36.
20. Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA: Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer 2007, 55(2):187-194.
21. Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, Fisher B, Eisenhauer E: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001, 92(3):595-600.
22. Garin A, Manikhas A, Biakhov M, Chezhin M, Ivanchenko T, Krejcy K, Karaseva V, Tjulandin S: A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2008, 110(2):309-315.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92(3):205-216.
24. Investigator's handbook: A manual for participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment National Cancer Institute [http://ctep.cancer.gov/investigatorResources/investigators-handbook.htm].
25. Simon R: Optimal two-stage designs for phase II clinical trials. Controlled Clini Trials 1989, 10:1-10.
26. Stallard N, Cockey L: Two-stage designs for phase II cancer trials with ordinal responses. Contemp Clin Trials 2008, 29(6):896-904.
27. Logan BR: Optimal two-stage randomized phase II clinical trials. Clin Trials 2005, 2(1):5-12.
28. Ye F, Shyr Y: Balanced two-stage designs for phase II clinical trials. Clin Trials 2007, 4(5):514-524.
29. Manegold C, Gatzemeier U, von Pawel J, Pirker R, Malayeri R, Blatter J, Krejcy K: Front-line treatment of advanced non-small-cell lung cancer with MTA (LY23 pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial. Ann Oncol 1514, 11(4):435-440.
30. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ: Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003, 21 (8): 1556-1561.
31. Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ: Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009, 27(12):2038-2045.
32. Monnerat C, Le Chevalier T: Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Ann Oncol 2006, 17(Suppl 5):86-90.